SOCS3 and metabolic dysfunction-associated steatohepatitis: Although it was reported that linagliptin inhibits hepatic SOCS3 expression in NAFLD and NASH mice [5, 30], we failed to find a significant reduction of SOCS3 mRNA expression in the liver after treatment with linagliptin.